CLOVER HEALTH INVESTMENTS, CORP. current report, 30 November 2023

Full document

Business Context and Reporting Period

Clover Health Investments, Corp. filed a Form 8-K dated November 30, 2023, with the report signed and furnished on December 1, 2023. The filing concerns the Company’s decision to exit the Centers for Medicare and Medicaid Services ACO REACH Program at the end of the 2023 performance year.

Financial Impact and Key Metrics

  • The Company expects total exit-related charges of approximately $8 million to $10 million.
  • The majority of the charges are expected to be non-cash.
  • An estimated $6 million non-cash impairment charge is expected to be recorded in the fourth quarter of 2023.
  • Additional charges include severance and legal costs, some of which may require future cash expenditures.
  • The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or balance-sheet figures.

Material Changes Versus the Prior Comparable Period

The Company is moving from a previously announced reduction in the number of ACO REACH participating physicians for 2023 to a full exit from the program. The Company stated that the exit was determined to be in its best interest. Exit activities are expected to conclude by the end of 2024.

Outlook, Risks, and Unusual Items

  • The Company provided no broader financial guidance in the filing.
  • Expected charges, impairment amounts, future cash expenditures, liquidity, profitability, and operating results are forward-looking and may differ materially from actual results.
  • The filing identifies risks and uncertainties described in the Company’s latest Form 10-K, subsequent Forms 10-Q, and other SEC filings.
  • The December 1, 2023 press release announcing the exit was furnished as Exhibit 99.1.

Important Facts for Investors to Verify

  • Actual fourth-quarter 2023 impairment charge and total exit-related charges.
  • Cash versus non-cash composition of severance, legal, and other exit costs.
  • Timing and completion of exit activities through the end of 2024.
  • Any effects of the ACO REACH exit on revenue, operating results, liquidity, and future strategy in subsequent filings.